Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Neural Transmission - Parkinsons Disease and Dementia Section

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/BF02251133PMID 1712206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of age on the activity and molecular properties of human brain monoamine oxidase

  2005cited by this paper
• Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

  2004cited by this paper
• Cognitive effects of l-deprenyl in Alzheimer's disease

  2004cited by this paper
• Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease

  2004cited by this paper
• Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

  2004cited by this paper
• Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity

  1990cited by this paper
• Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

  1990cited by this paper
• Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing presenile familial and sporadic senile cases.

  1989cited by this paper
• Dementia, ageing, and the structure of human memory.

  1988cited by this paper
• Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.

  1988cited by this paper
• L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.

  1987cited by this paper
• Determination of free 3-methoxy-4-hydroxyphenylethyleneglycol in plasma and in cerebrospinal fluid by liquid chromatography with coulometric detection.

  1987cited by this paper
• A rapid and simple method for determining catecholamines in human plasma and cerebrospinal fluid using high-performance liquid chromatography with electrochemical detection.

  1986cited by this paper
• A rapid and simple method for determining catecholamines in human plasma and cerebrospinal fluid using high-performance liquid chromatography with electrochemical detection.

  1986cited by this paper
• Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.

  1985cited by this paper
• Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer‐Type Dementia

  1984influential reference
• Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Platelet MAO activity in primary degenerative dementia.

  1984cited by this paper
• Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease.

  1984cited by this paper
• Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

  1983cited by this paper
• Monoamine metabolism in senile dementia of Alzheimer type.

  1983cited by this paper
• L-Deprenil, A Selective Monoamine Oxidase Type B Inhibitor, in the Treatment of Depression: A Double Blind Evaluation

  1983cited by this paper
• A new rating scale for dementia syndromes.

  1982cited by this paper
• The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.

  1982cited by this paper
• A new rating scale for dementia syndromes.

  1982cited by this paper
• Reduced lumbar CSF somatostatin levels in Alzheimer's disease.

  1982cited by this paper
• Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia

  1982cited by this paper
• (‐)Deprenyl in the Treatment of Parkinson's Disease

  1982cited by this paper
• The Global Deterioration Scale for assessment of primary degenerative dementia.

  1982influential reference
• Homovanillic acid and 5‐hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type

  1981cited by this paper
• Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

  1981cited by this paper
• [Dopaminergic A10 neurons and frontal system (author's transl)].

  1981cited by this paper
• Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.

  1981cited by this paper
• Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type.

  1980cited by this paper
• Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease.

  1980cited by this paper
• Neurotransmitter-related enzymes in senile dementia of the Alzheimer type.

  1979cited by this paper
• Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type

  1979cited by this paper
• Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’

  1978cited by this paper
• Constructional apraxia in left brain-damaged patients: a planning disorder?

  1977cited by this paper
• Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

  1977cited by this paper
• Deprenyl in Parkinson's disease.

  1977cited by this paper
• DETERMINATION OF MONOAMINE AND MONOAMINE METABOLITES IN THE HUMAN BRAIN: POST MORTEM STUDIES IN A GROUP OF SUICIDES AND IN A CONTROL GROUP

  1976cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975influential reference
• Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

  1971cited by this paper
• Homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile and presenile dementia.

  1970cited by this paper
• The Investigation of Homovanillic Acid in the Human Brain and its Correlation to Senile Dementia

  1969cited by this paper
• HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN THE CEREBROSPINAL FLUID OF PATIENTS WITH SENILE DEMENTIA, PRESENILE DEMENTIA AND PARKINSONISM

  1969cited by this paper
• Constructional Apraxia and Hemispheric Locus of Lesion

  1964cited by this paper
• A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

  1962cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960influential reference
• L’examen Clinique en Psychologie

  1959cited by this paper
• The measurement and appraisal of adult intelligence, 4th ed.

  1958cited by this paper

• Dopamine System Dysfunction in Alzheimer's Disease

  2025cites this paper
• Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis

  2023cites this paper
• CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and meta‐analysis

  2021cites this paper
• New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids.

  2021cites this paper
• Alzheimer’s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms

  2019cites this paper
• Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis

  2018cites this paper
• Monoaminergic neuropathology in Alzheimer's disease

  2017cites this paper
• Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?

  2016cites this paper
• Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review.

  2015cites this paper
• The subthalamic dopamine D5 receptors in Parkinson’s disease

  2014cites this paper
• Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

  2014cites this paper
• Serotonin transporter polymorphismen in VITA-Projekt

  2011cites this paper
• Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer

  2010cites this paper
• Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease — effect of L-Dopa

  2005cites this paper
• Effect of oral administration of zanapezil (TAK‐147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats

  2005cites this paper
• Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients

  2004cites this paper
• Perspectives on MAO-B in aging and neurological disease

  2004cites this paper
• Selegiline for Alzheimer's disease.

  2003cites this paper
• Biological Correlates of Clinical Subgroups of Alzheimer’s Disease

  2002cites this paper
• The effect of selegiline in the treatment of people with Alzheimer's disease: a meta‐analysis of published trials

  2002cites this paper
• Neue Aspekte in der antidementiven Pharmakotherapie der Alzheimer-Erkrankung

  2000cites this paper
• Therapie von oxidativem Streß

  1999cites this paper
• An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration.

  1999cites this paper
• Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.

  1998cites this paper
• Free radicals in Alzheimer's dementia: currently available therapeutic strategies.

  1998cites this paper
• L-deprenyl in Alzheimer's disease

  1998cites this paper
• [Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies].

  1997cites this paper
• Biphasic and region-specific MAO-B response to aging in normal human brain.

  1997cites this paper
• Pharmakotherapie bei Alzheimer-Demenz: Therapie kognitiver Symptome - neue Studienresultate

  1997cites this paper
• The effects of L-deprenyl on spatial short term memory in young and aged dogs.

  1996cites this paper
• Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.

  1996cites this paper
• Modulation of gene expression rather than monoamine oxidase inhibition

  1996cites this paper
• (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.

  1996cites this paper
• Deprenyl — Past and Future

  1996cites this paper
• Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type

  1995cites this paper
• Current pharmacological strategies in Alzheimer's disease

  1995cites this paper
• High-dose selegiline in treatment-resistant older depressive patients.

  1994cites this paper
• Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition.

  1994cites this paper
• Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons.

  1994cites this paper
• Age-related memory decline and longevity under treatment with selegiline.

  1994cites this paper
• Pharmacological and clinical implications of MAO-B inhibitors.

  1994cites this paper
• Repeated administrations of (-)-deprenyl increase [3H]MK801 binding in rat brain and antagonize the impairment of passive avoidance conditioning induced by N-methyl-D-aspartate receptor antagonists.

  1994cites this paper
• Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease

  1993cites this paper
• Selegiline can mediate neuronal rescue rather than neuronal protection

  1993cites this paper
• MAO-B Inhibitors in Neurological Disorders with Special Reference to Selegiline

  1993cites this paper
• Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition

  1993cites this paper
• Is ammonia a pathogenetic factor in Alzheimer's disease?

  1993cites this paper
• The new generation of monoamine oxidase inhibitors.

  1992cites this paper
• Deprenyl reduces the death of motoneurons caused by axotomy

  1992cites this paper